PSMA PET/CT在前列腺癌放疗前分期中的病灶检出水平与分布模式
结果显示71.3%患者PET阳性,PSA水平是唯一与PET阳性相关的因素,PSMA PET/CT较CT显著提高局部复发、淋巴结和远处转移的检出率,并导致56.6%患者放疗方案调整。
要点
- PSA水平是68Ga-PSMA PET/CT检出的唯一相关因素。
- PSMA PET/CT较CT显著提高局部复发、淋巴结及远处转移检出率。
- 56.6%患者因PSMA PET/CT结果调整放疗方案。
核心结论
- 前列腺癌病灶检出与68Ga-PSMA PET/CT时的PSA水平强相关。
- PSMA PET/CT可区分局部、区域和远处转移病变并影响疾病管理。
- PSMA PET/CT使前列腺切除术后PSA≤0.5 ng/ml拟行挽救性放疗的患者可检出肿瘤。
研究设计与样本
- 采用逻辑回归分析评估雄激素剥夺治疗、68Ga-PSMA-HBED-CC用量、PSA倍增时间≤/>10个月、PET/CT前PSA、T/N分期和Gleason评分等潜在影响因素。
- 比较PSMA PET/CT与增强CT的检出率并分析其对放疗管理的影响。
主要发现
- 71.3%患者PET阳性(PSA复发55.1%、PSA持续75%、初诊100%)。
- 有病理发现患者(n=92)PET/CT前中位PSA为1.90 ng/ml,无病理发现者(n=37)为0.30 ng/ml。
- PSA≤0.2 ng/ml、0.21-0.5 ng/ml、0.51-1.0 ng/ml时任何病灶检出率分别为33.3%、41.2%、69.2%。
- 复发或持续患者中42.2%有盆腔淋巴结转移、14.7%有远处转移;初诊患者盆腔淋巴结和远处转移检出率分别为20%和10%。
- 拟行挽救性放疗患者中,前列腺窝外复发检出率为盆腔淋巴结22.4%、远处转移4.1%。
关键数值与推荐
- PSMA PET/CT诊断局部复发/原发肿瘤灵敏度38% vs CT 10.1%。
- PSMA PET/CT诊断淋巴结灵敏度38.8% vs CT 15.5%。
- PSMA PET/CT诊断远处转移灵敏度14.0% vs CT 5.4%。
- 56.6%患者放疗方案因PSMA PET/CT结果而调整。
临床怎么用
- 前列腺癌放疗前分期可考虑68Ga-PSMA PET/CT以检出CT难以发现的局部、区域或远处病灶。
- 根治性前列腺切除术后PSA≤0.5 ng/ml拟行挽救性放疗者,PSMA PET/CT有助于肿瘤检出。
- PSMA PET/CT结果可影响放疗方案制定,需结合PSA水平解读检出结果。
局限性
- 回顾性分析设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine the potential role of 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) in radiotherapy (RT) planning for prostate cancer (PCa). METHODS: One hundred twenty-nine patients (pts) with 68Ga-PSMA PET/CT were retrospectively analysed. Potentially influencing factors (androgen deprivation therapy, amount of 68Ga-PSMA-HBED-CC, PSA doubling time ≤/> 10 months, PSA before PET/CT, T-/N-category and Gleason score) were evaluated by logistic regression analysis. The detection rate of PSMA PET/CT was compared to contrast enhanced CT and its impact on RT management analysed. RESULTS: One hundred twenty-nine patients (pts) (20 at initial diagnosis, 49 with PSA relapse and 60 with PSA persistence after radical prostatectomy) received PSMA PET/CT prior to RT. The majority of pts. (71.3%) had PET-positive findings (55.1% of pts. with PSA recurrence, 75% of pts. with PSA persistence and 100% of newly diagnosed pts). Median PSA before PET/CT in pts. with pathological findings (n = 92) was 1.90 ng/ml and without (n = 37) 0.30 ng/ml. PSA level at time of PET/CT was the only factor associated with PET-positivity. In pts. with a PSA ≤ 0.2 ng/ml, the detection rate of any lesion was 33.3%, with a PSA of 0.21-0.5 ng/ml 41.2% and with a PSA of 0.51-1.0 ng/ml 69.2%, respectively. Regarding the anatomic distribution of lesions, 42.2% and 14.7% of pts. with relapse or persistence had pelvic lymph node and distant metastases. In pts. at initial diagnosis the detection rate of pelvic lymph nodes and distant metastases was 20% and 10%. 68Ga-PSMA PET/CT had a high detection rate of PCa recurrence outside the prostatic fossa in pts. being considered for salvage RT (22.4% PET-positive pelvic lymph nodes and 4.1% distant metastases). Compared to CT, PSMA PET/CT had a significantly higher sensitivity in diagnosing rates of local recurrence/primary tumour (10.1% vs. 38%), lymph nodes (15.5% vs. 38.8%) and distant metastases (5.4% vs. 14.0%). This resulted in a modification of RT treatment in 56.6% of pts. CONCLUSIONS: The detection of PCa is strongly associated with PSA level at time of 68Ga-PSMA PET/CT. PSMA PET/CT differentiates between local, regional and distant metastatic disease with implications for disease management. PSMA PET/CT allows for tumour detection in post-prostatectomy pts. with PSA ≤ 0.5 ng/ml considered for salvage RT.
引用
- Schmidt-Hegemann NS, Fendler WP, Buchner A, et al. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiat Oncol. 2017. PMID: 29126446. doi:10.1186/s13014-017-0902-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。